Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrathecal Azacitidine and Nivolumab in Recurrent High-grade Glioma
NCT06896110Phase 1Enrolling by invitation
- Start
- Jun 2025
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of azacitidine and nivolumab in glioma. Primary endpoints: Incidence of adverse events at 24 months, Maximum tolerated dose at 24 months and 1 more. Started Jun 2025; status: enrolling by invitation.
02
Drugs
azacitidinenivolumab
03
Conditions
glioma
Beyond the preview
Go deeper on NCT06896110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06896110.